- Home
- ESEA vs CLLS Comparison
ESEA vs CLLS Comparison
Compare ESEA & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESEA | CLLS |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | Greece | France |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.3M | 374.2M |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ESEA | CLLS |
|---|---|---|
| Price | $64.12 | $3.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $62.00 | $8.50 |
| AVG Volume (30 Days) | ★ 57.6K | 30.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.49 | $40.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.30 | $1.10 |
| 52 Week High | $72.87 | $5.48 |
Technical Indicators
Market Signals| Indicator | ESEA | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 42.55 |
| Support Level | $51.63 | $3.41 |
| Resistance Level | $72.87 | $3.77 |
| Average True Range (ATR) | 3.46 | 0.17 |
| MACD | 0.21 | -0.02 |
| Stochastic Oscillator | 50.32 | 15.58 |
Price Performance
Historical ComparisonAbout ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.